Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market…
Cardiovascular
-
-
New screening recommendations for critical congenital heart defects
In December 2024, the American Academy of Pediatrics published an updated screening algorithm for critical congenital heart defects (CCHD). According…
-
Sequana Medical’s DSR 2.0 outperforms traditional peritoneal dialysis solutions in study
Following positive data reported earlier this year from a Phase I/II trial, Sequana Medical has touted results from a study…
-
Work-related stress connected to poorer cardiac health
According to a 2023 survey by the American Psychiatric Association, work-related stress affects approximately 77% of the US working population.…
-
AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 receptor (GLP-1R)…
-
Boston Scientific resumes enrolment in pulsed field ablation trial
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a…
-
Penumbra reveals positive data for algorithm-assisted thrombectomy tech
Penumbra has posted positive data for its computer-assisted vacuum thrombectomy (CAVT) technology aimed at treating patients with intermediate-risk pulmonary embolism…
-
Abbott touts long-term efficacy for dissolvable Esprit BTK stent
Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral…
-
J&J’s Shockwave deal pays off as IVL catheter meets primary endpoint in trial
Johnson & Johnson’s (J&J) Shockwave Medical unit has reported that its Javelin peripheral intravascular lithotripsy (IVL) catheter system successfully met…
-
Abbott starts new trial to assess early use benefit of HeartMate 3
Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit from early advanced therapy…
